Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 6
1967 13
1968 15
1969 14
1970 8
1971 16
1972 10
1973 25
1974 22
1975 18
1976 23
1977 21
1978 32
1979 23
1980 10
1981 21
1982 20
1983 25
1984 33
1985 24
1986 36
1987 21
1988 23
1989 37
1990 45
1991 29
1992 46
1993 38
1994 56
1995 46
1996 40
1997 68
1998 49
1999 65
2000 46
2001 60
2002 54
2003 61
2004 69
2005 60
2006 58
2007 49
2008 55
2009 48
2010 41
2011 36
2012 52
2013 38
2014 22
2015 27
2016 27
2017 20
2018 20
2019 21
2020 21
2021 12
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,780 results
Results by year
Filters applied: . Clear all
Page 1
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Hamilton SH, et al. Pharmacoeconomics. 1999 May;15(5):469-80. doi: 10.2165/00019053-199915050-00005. Pharmacoeconomics. 1999. PMID: 10537964 Clinical Trial.
MAIN OUTCOME MEASURES AND RESULTS: After acute treatment, BPRS-based clinical improvements were seen in 38 and 27% of olanzapine and haloperidol patients, respectively (p = 0.002). Clinically important improvements on the Quality of Life Scale were achieved during acute tr …
MAIN OUTCOME MEASURES AND RESULTS: After acute treatment, BPRS-based clinical improvements were seen in 38 and 27% of olanzapine and halo …
A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, Thavundayil JX, Achim A, Lizondo E, Nayak R. Vasavan Nair NP, et al. J Clin Psychopharmacol. 1986 Feb;6(1 Suppl):30S-37S. doi: 10.1097/00004714-198602001-00006. J Clin Psychopharmacol. 1986. PMID: 3514689 Clinical Trial.
Thirty patients with chronic schizophrenia received oral haloperidol and haloperidol decanoate in a two-phase open study. In the first phase, patients were stabilized on haloperidol tablets for 2 weeks, then maintained on a constant daily dose for 2 more week …
Thirty patients with chronic schizophrenia received oral haloperidol and haloperidol decanoate in a two-phase open study. In t …
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G, Annable L, Campbell W. Chouinard G, et al. J Clin Psychopharmacol. 1989 Aug;9(4):247-53. J Clin Psychopharmacol. 1989. PMID: 2570086 Clinical Trial.
We carried out an 8-month double-blind clinical trial comparing haloperidol decanoate with fluphenazine decanoate in the maintenance treatment of 72 schizophrenic outpatients. ...Both drugs had a similar profile for drug-induced parkinsonism, but there was a trend for diff …
We carried out an 8-month double-blind clinical trial comparing haloperidol decanoate with fluphenazine decanoate in the maintenance …
Treatment of Headache in the Emergency Department: Haloperidol in the Acute Setting (THE-HA Study): A Randomized Clinical Trial.
McCoy JJ, Aldy K, Arnall E, Petersen J. McCoy JJ, et al. J Emerg Med. 2020 Jul;59(1):12-20. doi: 10.1016/j.jemermed.2020.04.018. Epub 2020 May 10. J Emerg Med. 2020. PMID: 32402480 Clinical Trial.
Thirty-four patients (58.6%) in the haloperidol group had complete resolution of their headache. Treatment with rescue ketorolac was required in 78.3% of the control group and 31% of the haloperidol group. Adverse events were uncommon, benign, and easily treated. No …
Thirty-four patients (58.6%) in the haloperidol group had complete resolution of their headache. Treatment with rescue ketorolac was …
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Kane JM, et al. J Clin Psychopharmacol. 2010 Apr;30(2):106-15. doi: 10.1097/JCP.0b013e3181d35d6b. J Clin Psychopharmacol. 2010. PMID: 20520283 Clinical Trial.
Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively. Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BI …
Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and pl …
Comparative trial of the antiemetic effects of THC and haloperidol.
Neidhart JA, Gagen MM, Wilson HE, Young DC. Neidhart JA, et al. J Clin Pharmacol. 1981 Aug-Sep;21(S1):38S-42S. doi: 10.1002/j.1552-4604.1981.tb02571.x. J Clin Pharmacol. 1981. PMID: 6271838 Clinical Trial.
A prospective, randomized and double-blinded trial of the comparative effects of delta-9-tetrahydrocannabinol (THC) and haloperidol (H) was begun in February 1980. Patients were randomized to initially receive either THC or haloperidol with cross-over to the other a …
A prospective, randomized and double-blinded trial of the comparative effects of delta-9-tetrahydrocannabinol (THC) and haloperidol ( …
Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T, Marder SR, Mintz J, Poland RE. Van Putten T, et al. Am J Psychiatry. 1992 Apr;149(4):500-5. doi: 10.1176/ajp.149.4.500. Am J Psychiatry. 1992. PMID: 1554036 Clinical Trial.
OBJECTIVE: The purpose of the study was to assess the relationship between plasma haloperidol and clinical response. METHOD: Sixty-nine newly admitted drug-free schizophrenic men were randomly assigned to receive haloperidol, 5, 10, or 20 mg daily for 4 weeks, and c …
OBJECTIVE: The purpose of the study was to assess the relationship between plasma haloperidol and clinical response. METHOD: Sixty-ni …
Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Chou JC, et al. Psychiatry Res. 1998 Oct 19;81(1):51-5. doi: 10.1016/s0165-1781(98)00085-7. Psychiatry Res. 1998. PMID: 9829650 Free article. Clinical Trial.
In this study, 23 acutely exacerbated schizophrenic and schizoaffective patients were washed out for at least 6 days and were then treated with haloperidol to achieve fixed low to moderate plasma levels under double-blind conditions. Clinical response, plasma prolactin, an …
In this study, 23 acutely exacerbated schizophrenic and schizoaffective patients were washed out for at least 6 days and were then treated w …
Blood levels of haloperidol and clinical outcome in schizophrenia.
Doddi S, Rifkin A, Karajgi B, Cooper T, Borenstein M. Doddi S, et al. J Clin Psychopharmacol. 1994 Jun;14(3):187-95. J Clin Psychopharmacol. 1994. PMID: 8027415 Clinical Trial.
Haloperidol levels in blood were measured in 55 acutely psychotic inpatients with schizophrenia, who were randomly assigned to three fixed doses of oral haloperidol. ...All of the subjects were treated under double-blind conditions for 6 weeks or until remission. …
Haloperidol levels in blood were measured in 55 acutely psychotic inpatients with schizophrenia, who were randomly assigned to three …
Prophylactic Use of Haloperidol and Changes in Glucose Levels in Hospitalized Older Patients.
van Keulen K, Knol W, Schrijver EJM, van Marum RJ, van Strien AM, Nanayakkara PWB. van Keulen K, et al. J Clin Psychopharmacol. 2018 Feb;38(1):51-54. doi: 10.1097/JCP.0000000000000812. J Clin Psychopharmacol. 2018. PMID: 29210808 Clinical Trial.
The aim of this study was to investigate changes in glucose levels during haloperidol use compared with the use of placebo among older hospitalized patients. ...Participating patients were randomized for treatment and given 1 mg of haloperidol or a placebo twice dai …
The aim of this study was to investigate changes in glucose levels during haloperidol use compared with the use of placebo among olde …
1,780 results